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7 Summary 
 
Effects of the A1-adenosine receptor antagonist SLV320 on the progression of 
interstitial myocardial fibrosis in a model of 5/6-nephrectomized rats 
 
Patients with kidney disease have a high burden of cardiovascular illness. Uremic 
cardiomyopathy contains left-ventricular hypertrophy, myocardial interstitial fibrosis and 
myocardial infarction. Atherosclerosis and anemia are also components. 
The treatment of the cardiovascular complications in patients with end-stage renal disease is 
so far unsatisfactory; these complications are the leading cause of death in this population. 
Myocardial interstitial fibrosis is one of the main components of uremic cardiomyopathy and 
can cause impaired diastolic elasticity, malfunction in cardiac conduction, as well as ischemia 
with subsquent myocardial infarction. 
Adenosine is an endogene-produced nucleoside that occurs in any living cell. In addition to 
its manifold functions in cellular metabolism this nucleoside plays an important role as a 
signal transductor in the cardiovascular system.   
Via the A2b-adenosine receptor, adenosine influences the collagen- and protein-synthesis in 
cardiofibroblasts. 
SLV320 is a selective A1-adenosine receptor antagonist. In this study the effects of SLV320 
on the progression of the interstitial myocardial fibrosis in an organism with experimental 
renal failure were investigated. 
The 5/6-nephrectomy model with rats was selected. Young male Sprague-Dawley rats were 
5/6-nephrectomized in two steps. Animals for control groups were sham operated: both 
kidneys were decapsulated.  Animals were then randomly divided into groups and given the 
substance SLV320 or a placebo. 
At the end of 12 weeks animals were killed and their hearts and kidneys, or what was left of 
the kidney, were extracted and preserved in formaldehyde. 
Chemical blood tests proved chronic renal failure in the 5/6-nephrectomized rats. 
Increased myocardial interstitial fibrosis was found in uremic animals. Enhanced plasma-
activity of the enzymes CK, ALT and AST was also found. 
Interstitial myocardial fibrosis was significantly reduced in SLV320-treated uremic rats when 
compared with those that were untreated. Moreover, the plasma-activity of the muscle 
enzymes was significantly decreased. 
The antifibrotic effect of SLV320 may offer a chance to treat an important component of 
uremic cardiomyopathy. More studies are necessary to clarify whether the effect on the 
enzymes is independent or dependent on the antifibrotic effect. 
 55  
The molecular mechanisms with which SLV320 works must be investigated in order to make 
possible its therapeutic use in the treatment of uremic cardiomyopathy. 
